Teva Pharmaceuticals (NYSE:TEVA) announced today that it launched generic Erythromycin oral tablets in the U.S.
Parsippany, N.J.-based Teva — a U.S. affiliate of Tel Aviv, Israel-based Teva Pharmaceutical Industries — launched the 250 mg- and 500 mg-strength generic Erythromycin tablets, which are a therapeutic equivalent for the reference listed drug Erythromycin from Arbor Pharmaceuticals, according to a news release.
Teva’s generic Erythromycin tablets are indicated for treating a number of bacterial infections and to prevent initial or recurrent attacks of rheumatic fever in patients allergic to penicillin.
Erythromycin treats infections caused by specific, susceptible strains of microorganisms in diseases including respiratory tract infections, listeriosis, skin and skin structure infections, pertussis (whooping cough), diphtheria, erythrasma, intestinal amebiasis, acute pelvic inflammatory disease, conjunctivitis in newborns, pneumonia of infancy, urogenital infections during pregnancy, uncomplicated urethral, endocervical, or rectal infections in adults in specific situations; nongonococcal urethritis in specific situations, primary syphilis and Legionnaires’ Disease.
Teva said IQVIA data from January 2021 claims that U.S. sales of Erythromycin oral tablets total more than $49 million annually.
